Biocryst Pharmaceuticals (BCRX) Cash from Operations (2010 - 2026)

Biocryst Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 61791000.0 for Q1 2026.

• Quarterly Cash from Operations fell 124.56% year-over-year to 61791000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 313095000.0 (up 1311.06% YoY) and the FY2025 annual result came in at 347369000.0, up 767.76% from the prior year.
• Cash from Operations was 61791000.0 for Q1 2026 at Biocryst Pharmaceuticals, down from 291960000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 291960000.0 in Q4 2025 and bottomed at 77800000.0 in Q1 2022.
• A 5-year average of 1378411.76 and a median of 19897000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2025 — Cash from Operations soared 5700.61% — and 2026, when it sank 124.56%.
• Biocryst Pharmaceuticals' Cash from Operations stood at 23849000.0 in 2022, then surged by 62.61% to 8918000.0 in 2023, then soared by 41.55% to 5213000.0 in 2024, then surged by 5700.61% to 291960000.0 in 2025, then slumped by 121.16% to 61791000.0 in 2026.
• Business Quant data shows BCRX's Cash from Operations at 61791000.0 in Q1 2026, 291960000.0 in Q4 2025, and 41624000.0 in Q3 2025.